Literature DB >> 11902586

Immune evasion in human papillomavirus-associated cervical cancer.

Robert W Tindle1.   

Abstract

Tumour-associated viruses produce antigens that, on the face of it, are ideal targets for immunotherapy. Unfortunately, these viruses are experts at avoiding or subverting the host immune response. Cervical-cancer-associated human papillomavirus (HPV) has a battery of immune-evasion mechanisms at its disposal that could confound attempts at HPV-directed immunotherapy. Other virally associated human cancers might prove similarly refractive to immuno-intervention unless we learn how to circumvent their strategies for immune evasion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11902586     DOI: 10.1038/nrc700

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  108 in total

1.  The mechanisms of inactivation of the Tag7-Hsp70 cytotoxic complex.

Authors:  D V Yashin; E A Dukhanina; O D Kabanova; E A Romanova; T I Lukyanova; A A Sheludchenkov; Yu K Sykulev; N V Gnuchev; L P Sashchenko
Journal:  Dokl Biol Sci       Date:  2012-03-17

2.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

3.  Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.

Authors:  Andrés Báez-Astúa; Elsa Herráez-Hernández; Natalio Garbi; Hilda A Pasolli; Victoria Juárez; Harald Zur Hausen; Angel Cid-Arregui
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy.

Authors:  Matthieu Perreau; Franck Mennechet; Nicolas Serratrice; Joel N Glasgow; David T Curiel; Harald Wodrich; Eric J Kremer
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Cervical cancer and CYP2E1 polymorphisms: implications for molecular epidemiology.

Authors:  Paula M Ferreira; Raquel Catarino; Deolinda Pereira; Ana Matos; Daniela Pinto; Ana Coelho; Carlos Lopes; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2005-12-22       Impact factor: 2.953

Review 6.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

7.  Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.

Authors:  Nicholas C Souders; Duane A Sewell; Zhen-Kun Pan; S Farzana Hussain; Alexander Rodriguez; Anu Wallecha; Yvonne Paterson
Journal:  Cancer Immun       Date:  2007-02-06

Review 8.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

9.  Reduced expression of members of the mhc-i antigen processing machinery in ethnic Uighur women with cervical cancer in the Xinjiang region of China.

Authors:  A Haimiti; Y Hailiman; A Gulina; J Du; Z Hao; X L Rong; A Zainuer; W Qin; S Lalai
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

10.  Nanog signaling in cancer promotes stem-like phenotype and immune evasion.

Authors:  Kyung Hee Noh; Bo Wook Kim; Kwon-Ho Song; Hanbyoul Cho; Young-Ho Lee; Jin Hee Kim; Joon-Yong Chung; Jae-Hoon Kim; Stephen M Hewitt; Seung-Yong Seong; Chih-Ping Mao; T-C Wu; Tae Woo Kim
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.